The reduction of a chemical called GM3 through genetic modification prevents the development of neuropathies in mice with diabetic obesity.
A study published in Molescular Pain states that the reduction of GM3 by genetic manipulation prevents the development of neuropathies in mice with diabetic obesity.
Researchers are developing a genetic treatment ointment to reduce GM3 and the GM3 synthase, the enzyme produced by GM3.The objective is that the GM3 reduction ointment, applied in the mice leg with diabetes, may prevent or even better, reverse the existing neuropathy.
"We have terrible treatments for diabetic neuropathy," says Dr. Amy Paller, principal researcher at Northwestern University."We just treat pain but not the disease," adds it.
